Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

PBC is the most frequent CD-related liver disease, being regarded as the most prevalent autoimmune disorder detected in CD after Hashimoto thyroiditis, Type 1 diabetes mellitus and Sjogren syndrome.

PBC is a rare and chronic liver disease that disproportionately affects women. The condition causes the small bile ducts in the liver to become inflamed and destroyed, resulting in damage to liver ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

Treatments for autoimmune hepatitis and primary biliary cirrhosis In both of these diseases, your body’s natural defense system (the immune system) attacks and damages your liver. Primary ...

And there was.” Mandy, from Newcastle-under-Lyme in Staffordshire, was diagnosed with primary biliary cholangitis (PBC) a liver disease which causes liver failure. The condition also leaves ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Liver diseases are any diseases that affect the functioning of the liver. Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example ...

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...